STAT+: Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems
After a decade of manufacturing problems, a U.S. federal court ordered a unit of Wockhardt, one of the largest makers of generic drugs, to refrain from making allegedly adulterated medicines at a facility in Illinois. However, the U.S. subsidiary, Morton Grove Pharmaceuticals, recently decided to discontinue operations at the site, according to court documents.
The move came after the U.S. Department of Justice late last week filed a lawsuit alleging that Morton Grove failed to have adequate procedures to prevent cross contamination of equipment, failed to reject batches of that used a contaminated ingredient, and also failed to investigate how the contamination occurred.
